$4.83
+0.05 (+1.05%)
Open$4.67
Previous Close$4.78
Day High$5.08
Day Low$4.62
52W High$9.25
52W Low$3.91
Volume—
Avg Volume24.3K
Market Cap9.61M
P/E Ratio—
EPS$-17.79
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+446.0% upside
Current
$4.83
$4.83
Target
$26.37
$26.37
$21.16
$26.37 avg
$30.50
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 8.19M | 7.42M | 3.98M |
| Net Income | -35,505,028 | -28,962,680 | 267.7K |
| Profit Margin | -433.7% | -412.1% | 6.7% |
| EBITDA | -36,786,868 | -31,675,450 | 477.9K |
| Free Cash Flow | — | — | 225.1K |
| Rev Growth | +10.3% | +10.3% | +11.2% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |